UK markets closed

Hofseth BioCare ASA (0Q6H.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
2.0000-6.9000 (-77.53%)
At close: 05:40PM BST
Full screen
Previous close8.9000
Open8.0408
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range8.0408 - 8.0408
52-week range8.0408 - 8.0408
Volume11,112
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

    An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 30 August 2022 at 13:00 CET. Please find the notice to the General Meeting attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: joo@hofsethbiocare.no About Hofseth BioCare ASA HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new drug leads. Research is ongoing t

  • Globe Newswire

    Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

    In the annual general meeting of Hofseth BioCare ASA (the "Company") held on 29 April 2022, the general meeting resolved to carry out a private placement towards Brilliant Invest 2 AG as part of an incentive program for certain consultants and partners of the Company. Further, the Company carried out a private placement towards various investors on 3 July 2022. In the latter private placement, the payment dates were set in two tranches with the second tranche having payment date on 24 July 2022.

  • Globe Newswire

    Hofseth Biocare ASA: JON OLAV ØDEGÅRD APPOINTED NEW CEO OF HBC

    Following years of strong growth in Hofseth International AS ("Hofseth International") and the expected further positive development in Hofseth BioCare ASA's ("HBC") revenues and sales activities, it has been decided to strengthen management focus in both companies. Roger Hofseth will therefore continue to serve as CEO of Hofseth International but has decided to step back as CEO of HBC and change his involvement in the company to a director of the Board, as the nomination committee has asked the